<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814602</url>
  </required_header>
  <id_info>
    <org_study_id>3464</org_study_id>
    <nct_id>NCT04814602</nct_id>
  </id_info>
  <brief_title>Single-dose PK Assessment of Oral Proglumide in Those With Hepatic Impairment</brief_title>
  <acronym>HIPK</acronym>
  <official_title>Single-dose Pharmacokinetic (PK) Assessment of Oral Proglumide in Those With Hepatic Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Georgetown University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Georgetown University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proglumide is an oral cholecystokinin (CCK) receptor antagonist that has been shown in&#xD;
      non-clinical studies to reverse hepatic fibrosis and decrease the incidence of hepatocellular&#xD;
      carcinoma (HCC). Because of these potential beneficial properties, proglumide may be useful&#xD;
      in decreasing the fibrosis and risk for HCC in those with cirrhosis. Although proglumide is&#xD;
      safe in those with normal hepatic function, the pharmacokinetics have not been established in&#xD;
      those that are hepatic impaired. The purpose of this study is to analyze proglumide blood&#xD;
      levels and excretion in subjects with cirrhosis compared to health controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to measure blood levels of proglumide after a single oral dose&#xD;
      (400 mg) over a period of time and compare the blood levels to those with normal hepatic&#xD;
      function (N=4) to determine if there is delayed metabolism and clearance of proglumide in&#xD;
      those with hepatic impairment (HI) (N=8). Eligible subjects will provide a baseline blood and&#xD;
      urine sample prior to ingesting proglumide 400 mg po. Blood will be collected from an&#xD;
      intravenous catheter after ingestion at the following intervals: 1 hr, 3 hrs, 5 hrs, 7 hrs&#xD;
      and 24 hr (Â± 4-5 hours). After 3 hrs and 5 hrs subjects will provide a urine sample. Samples&#xD;
      will be analyzed by Mass Spectometry. Proglumide blood and urine levels in ng/ml will be&#xD;
      plotted over time and the Cmax (peak plasma concentration), Tmax (time to reach Cmax) and&#xD;
      T1/2 (elimination half time) calculated for each subject and compared to that of 4 healthy&#xD;
      controls.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>open labeled</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proglumide blood levels in hepatic impaired subjects</measure>
    <time_frame>24 hours</time_frame>
    <description>Proglumide levels in ng/ml in cirrhosis subjects compared to healthy controls</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urinary excretion of proglumide</measure>
    <time_frame>24 hours</time_frame>
    <description>Measurement of proglumide in urine after single does ingestion in cirrhosis compared to healthy controls</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls Proglumide 400 mg given once by mouth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatic Impaired</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cirrhosis Child-Pugh A and B Proglumide 400 mg given once by mouth</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Proglumide</intervention_name>
    <description>CCK receptor antagonist</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Hepatic Impaired</arm_group_label>
    <other_name>Milid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cirrhosis previously confirmed by one of the following: Liver biopsy, FibroScan,&#xD;
             FibroSure, MR-Elastography, or nodular liver on radiographic imaging like CT or MRI.&#xD;
             Child-Pugh classification A (N=4) and Child-Pugh classification B (N=4)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those that are Child-Pugh classification C cirrhosis&#xD;
&#xD;
          -  gastrointestinal bleeding from esophageal varices within 6 months&#xD;
&#xD;
          -  Chronic kidney disease with Estimated glomerular filtration rate (eGFR of &lt; 90&#xD;
             mL/min/1.73m2)&#xD;
&#xD;
          -  hepatic encephalopathy&#xD;
&#xD;
          -  those that have had an organ transplant&#xD;
&#xD;
          -  active hepatitis C, active hepatitis B, and those with HIV disease&#xD;
&#xD;
               -  Adults unable to consent&#xD;
&#xD;
               -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
               -  Pregnant women&#xD;
&#xD;
               -  Prisoners&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill P Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Georgetown University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jill P Smith, MD</last_name>
    <phone>2026872020</phone>
    <email>jps261@georgetown.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hong Cao, PhD</last_name>
    <phone>2026872020</phone>
    <email>hc87@georgetown.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Turner, BSN, RN, CPN</last_name>
      <phone>202-444-0796</phone>
      <email>kat59@georgetown.edu</email>
    </contact>
    <contact_backup>
      <last_name>Terry Jeffs, RN</last_name>
      <phone>1 202-444-0796</phone>
      <email>jeffsm@georgetown.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jill P Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine Hsu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Coleman Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Turner, BSN, RN, CPN</last_name>
      <phone>202-444-2639</phone>
      <email>kat59@georgetown.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 22, 2021</study_first_submitted>
  <study_first_submitted_qc>March 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proglumide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Will be published and placed on clinicaltrials website</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

